Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy

Breast Cancer Research and Treatment

Volumn 100, Issue 3, 2006, Pages 255-262

  Shayne, Michelle ^a   Crawford, Jeffrey ^b   Dale, David C ^c   Culakova, Eva ^a   Lyman, Gary H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adjuvant chemotherapy; Dose intensity; Early stage breast cancer

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; GROUPS BY AGE; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; KIDNEY DISEASE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; STANDARD; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS;

AGE FACTORS; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BODY SURFACE AREA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTH CARE SURVEYS; HUMANS; KIDNEY DISEASES; LYMPH NODES; MIDDLE AGED; NEUTROPENIA; ODDS RATIO; PATIENT SELECTION; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 33749831378     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9254-4     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687-1717
2. Bonadonna G, Valagussa P, Moliterni A et al (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of followup. N Engl J Med 332:901-906
3. Wood WC, Budman DR, Korzun AH et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259
4. Budman DR, Berry DA, Cirrincione CT et al (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211
5. Piccart MJ, Biganzoli L, Di Leo A (2000) The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 36(Suppl 1):S4-S10
6. Chang J (2000) Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36(Suppl 1):S11-S14
7. Adjuvant therapy for breast cancer (2000) NIH Consensus Statement 17:1-35
8. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431-1439
9. Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524-4531
10. Lyman GH, Dale DC, Friedberg J et al (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 22:4302-4311
11. Dale DC, McCarter GC, Crawford J et al (2003) Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. JNCCN 1:440-454
12. Harlan LC, Clegg LX, Abrams J et al (2006) Communitybased use of chemotherapy and hormonal therapy for earlystage breast cancer: 1987-2000. J Clin Oncol 24:872-877
13. Mayers C, Panzarella T, Tannock IF (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91:2246-2257
14. Cameron DA, Massie C, Kerr G et al (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89:1837-1842
15. Saarto T, Blomqvist C, Rissanen P et al (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75:301-305
16. Colleoni M, Price K, Catigione-Gertsch M et al (1998) Doseresponse effect of adjuvant cycloposphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 34:1693-1700
17. Bonneterre J, Roche H, Kerbrat P et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French adjuvant study group 05 randomized trial. J Clin Oncol 23:2686-2693
18. Hudis C, Citron M, Berry D et al (2005) Five year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 94:S20
19. Moliterni A, Bonadonna G, Valagussa P et al (1991) Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130
20. Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410
21. Buzdar AU, Hortobagyi GN, Kau S-W (1990) Doxorubicincontaining adjuvant therapy for patients with stage II breast cancer: MD Anderson Cancer Center experience. In: Salmon SE (eds) Adjuvant therapy of cancer VI. WB Saunders Co, Philadelphia, PA, pp 210-215
22. Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-non-responsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496
23. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983